Femara (letrazole) is being assessed at CORT in a Novartis study for patients who have had intolerance to Arimidex (anastrazole) because of joint of muscle pain. Patients who have had NCI-CTC grade >=2 arthralgias or myalgias are eligible. After a 2-week period of discontinuation of Arimidex, patients will receive Femara, with continued standardized assessments of their joint and muscle symptoms. Femara will be provided by the study. The study will determine is patients are better able to tolerate Femara for their continued therapy.
For more information about this study, call 972-566-5588 (Dallas) or 972-981-4012 (Plano), and ask to speak to a Research Coordinator. More information about CORT and CORT studies is available at www.CORTPA.com.
Tags: Anastrazole, Arimidex, Breast Cancer, Femara, Letrazole
